Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

被引：0
|
作者：
Shaohua Zhang
Lei Li
Tao Wang
Li Bian
Haixu Hu
Chunhong Xu
Bing Liu
Yi Liu
Massimo Cristofanilli
Zefei Jiang
机构：
[1] Affiliated Hospital of Academy of Military Medical Sciences,Department of Breast Cancer
[2] Affiliated Hospital of Academy of Military Medical Sciences,Translational Medicine Center, Laboratory of Oncology
[3] Jefferson University Hospital,Department of Medical Oncology
来源：
BMC Cancer | / 16卷
关键词：
Circulating Tumor Cells (CTCs); Human Epidermal Growth Factor Receptor 2 (HER2); Metastatic Breast Cancer (MBC); Anti-HER2 therapy; Real-time HER2 status;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
    N. M. Atallah
    M. Alsaleem
    M. S. Toss
    N. P. Mongan
    E. Rakha
    British Journal of Cancer, 2023, 129 : 1692 - 1705
  • [12] Reassessment of HER2 status in breast cancer patients with initially HER2 negative or HER2 unknown primary tumors at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, T.
    Solomayer, E.
    Uhr, J.
    Wallwiener, D.
    ONKOLOGIE, 2008, 31 : 51 - 51
  • [13] Clinical significance of metastatic-tumor HER2 status in patients with HER2-positive primary breast cancer
    Niikura, N.
    Liu, J.
    Hayashi, N.
    Mittendorf, E. A.
    Gong, Y.
    Palla, S. L.
    Tokuda, Y.
    Gonzalez-Angulo, A. M.
    Hortobagyi, G. N.
    Ueno, N. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [14] Utilization of anti-HER2 regimens among HER2-positive metastatic breast cancer patients.
    Mehta, Sandhya
    Song, Jinlin
    Pavilack, Melissa
    Xie, Jipan
    Nie, Xiaoyu
    Vembusubramanian, Mohini
    Kwong, Jackie
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
  • [15] Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells.
    Fehm, T.
    Lane, N.
    Solomayer, E.
    Wallwiener, D.
    Uhr, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S40
  • [16] HER2 mutation status in Japanese HER2-positive breast cancer patients
    Endo, Yumi
    Dong, Yu
    Kondo, Naoto
    Yoshimoto, Nobuyasu
    Asano, Tomoko
    Hato, Yukari
    Nishimoto, Mayumi
    Kato, Hiroyuki
    Takahashi, Satoru
    Nakanishi, Ryoichi
    Toyama, Tatsuya
    BREAST CANCER, 2016, 23 (06) : 902 - 907
  • [17] HER2 mutation status in Japanese HER2-positive breast cancer patients
    Yumi Endo
    Yu Dong
    Naoto Kondo
    Nobuyasu Yoshimoto
    Tomoko Asano
    Yukari Hato
    Mayumi Nishimoto
    Hiroyuki Kato
    Satoru Takahashi
    Ryoichi Nakanishi
    Tatsuya Toyama
    Breast Cancer, 2016, 23 : 902 - 907
  • [18] Targeting HER2 in patients with HER2-negative metastatic breast cancer with elevated serum levels of the HER2 extracellular domain and/or HER2-positive circulating tumor cells in the clinical routine
    Kurbacher, C. M.
    Quade, A.
    Kunstmann, G.
    Herz, S.
    Kurbacher, J. A.
    Warm, M. A.
    ANNALS OF ONCOLOGY, 2015, 26
  • [19] Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
    You, Ji Young
    Park, Kyoung Hwa
    Lee, Eun Sook
    Kwon, Youngmee
    Kim, Kyoung Tae
    Nam, Seungyoon
    Kim, Dong Hee
    Bae, Jeoung Won
    CANCER CONTROL, 2023, 30
  • [20] Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
    You, Ji Young
    Park, Kyoung Hwa
    Lee, Eun Sook
    Kwon, Youngmee
    Kim, Kyoung Tae
    Nam, Seungyoon
    Kim, Dong Hee
    Bae, Jeoung Won
    CANCER CONTROL, 2022, 29
12345